71 related articles for article (PubMed ID: 21391225)
1. RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway.
Wang S; Huang X; Li Y; Lao H; Zhang Y; Dong H; Xu W; Li JL; Li M
Hepatology; 2011 Jun; 53(6):1932-42. PubMed ID: 21391225
[TBL] [Abstract][Full Text] [Related]
2. EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling.
Liu ZK; Li C; Zhang RY; Wei D; Shang YK; Yong YL; Kong LM; Zheng NS; Liu K; Lu M; Liu M; Hu CX; Yang XZ; Chen ZN; Bian H
Mol Cancer; 2021 May; 20(1):79. PubMed ID: 34044846
[TBL] [Abstract][Full Text] [Related]
3. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.
Villanueva A; Alsinet C; Yanger K; Hoshida Y; Zong Y; Toffanin S; Rodriguez-Carunchio L; Solé M; Thung S; Stanger BZ; Llovet JM
Gastroenterology; 2012 Dec; 143(6):1660-1669.e7. PubMed ID: 22974708
[TBL] [Abstract][Full Text] [Related]
4. Testis-specific protein Y-encoded 1 regulates androgen receptor expression through the MAPK/ERK pathway in male hepatocellular carcinoma.
Lu Z; Yang D; Qin S; Mo C; Zhang L; Ou Y; Li S
Saudi Med J; 2022 Oct; 43(10):1087-1095. PubMed ID: 36261201
[TBL] [Abstract][Full Text] [Related]
5. Fibulin-2 Facilitates Malignant Progression of Hepatocellular Carcinoma.
Hu X; Liu T; Li L; Gan H; Wang T; Pang P; Mao J
Turk J Gastroenterol; 2023 Jun; 34(6):635-644. PubMed ID: 37162505
[TBL] [Abstract][Full Text] [Related]
6. Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology.
Yu JX; Craig AJ; Duffy ME; Villacorta-Martin C; Miguela V; Ruiz de Galarreta M; Scopton AP; Silber L; Maldonado AY; Rialdi A; Guccione E; Lujambio A; Villanueva A; Dar AC
Mol Cancer Ther; 2019 Sep; 18(9):1506-1519. PubMed ID: 31213506
[TBL] [Abstract][Full Text] [Related]
7. GRAMD4 inhibits tumour metastasis by recruiting the E3 ligase ITCH to target TAK1 for degradation in hepatocellular carcinoma.
Ge QY; Chen J; Li GX; Tan XL; Song J; Ning D; Mo J; Du PC; Liu QM; Liang HF; Ding ZY; Zhang XW; Zhang BX
Clin Transl Med; 2021 Nov; 11(11):e635. PubMed ID: 34841685
[TBL] [Abstract][Full Text] [Related]
8. Levofloxacin exerts broad-spectrum anticancer activity via regulation of THBS1, LAPTM5, SRD5A3, MFAP5 and P4HA1.
He X; Yao Q; Hall DD; Song Z; Fan D; You Y; Lian W; Zhou Z; Duan L; Chen B
Anticancer Drugs; 2022 Jan; 33(1):e235-e246. PubMed ID: 34419964
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ERK 1/2 kinases prevents tendon matrix breakdown.
Blache U; Wunderli SL; Hussien AA; Stauber T; Flückiger G; Bollhalder M; Niederöst B; Fucentese SF; Snedeker JG
Sci Rep; 2021 Mar; 11(1):6838. PubMed ID: 33767224
[TBL] [Abstract][Full Text] [Related]
10. Notch signaling in hepatocellular carcinoma: guilty in association!
Strazzabosco M; Fabris L
Gastroenterology; 2012 Dec; 143(6):1430-4. PubMed ID: 23099244
[No Abstract] [Full Text] [Related]
11. FBXL19 promotes malignant behaviours by activating MAPK signalling and negatively correlates with prognosis in hepatocellular carcinoma.
Xun M; Wang J; Xie Q; Peng B; Li Z; Guo Z; Zeng Y; Su H; Yao M; Liao L; Li Y; Yuan G; Chen S; He S
Heliyon; 2023 Nov; 9(11):e21771. PubMed ID: 38027627
[TBL] [Abstract][Full Text] [Related]
12. Chalcomoracin promotes apoptosis and endoplasmic reticulum stress in hepatocellular carcinoma cells.
Cui Y; Lan L; Lv J; Zhao B; Kong J; Lai Y
J Antibiot (Tokyo); 2024 May; ():. PubMed ID: 38724630
[TBL] [Abstract][Full Text] [Related]
13. A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer.
Tagaram HR; Desai D; Li G; Liu D; Rountree CB; Gowda K; Berg A; Amin S; Staveley-O'Carroll KF; Kimchi ET
Pharmaceuticals (Basel); 2016 Mar; 9(2):. PubMed ID: 27023566
[TBL] [Abstract][Full Text] [Related]
14. Notch-driven carcinogenesis: the merging of hepatocellular cancer and cholangiocarcinoma into a common molecular liver cancer subtype.
Razumilava N; Gores GJ
J Hepatol; 2013 Jun; 58(6):1244-5. PubMed ID: 23352938
[TBL] [Abstract][Full Text] [Related]
15. Sorbitol dehydrogenase induction of cancer cell necroptosis and macrophage polarization in the HCC microenvironment suppresses tumor progression.
Lee SY; Kim S; Song Y; Kim N; No J; Kim KM; Seo HR
Cancer Lett; 2022 Dec; 551():215960. PubMed ID: 36244575
[TBL] [Abstract][Full Text] [Related]
16. UBXN9 inhibits the RNA exosome function to promote T cell control of liver tumorigenesis.
Zhang L; Jiao K; Liu Y; Xu G; Yang Z; Xiang L; Chen Z; Xu C; Zuo Y; Wu Z; Zheng N; Zhang X; Xia Q; Liu Y
Hepatology; 2023 Dec; ():. PubMed ID: 38051955
[TBL] [Abstract][Full Text] [Related]
17. RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway.
Wang S; Wang X; Gao Y; Peng Y; Dong N; Xie Q; Zhang X; Wu Y; Li M; Li JL
J Pathol; 2019 Jun; 248(2):204-216. PubMed ID: 30714150
[TBL] [Abstract][Full Text] [Related]
18. RNF181 modulates Hippo signaling and triple negative breast cancer progression.
Zhou R; Ding Y; Xue M; Xiong B; Zhuang T
Cancer Cell Int; 2020; 20():291. PubMed ID: 32655323
[TBL] [Abstract][Full Text] [Related]
19. KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer.
Singel SM; Cornelius C; Zaganjor E; Batten K; Sarode VR; Buckley DL; Peng Y; John GB; Li HC; Sadeghi N; Wright WE; Lum L; Corson TW; Shay JW
Neoplasia; 2014 Mar; 16(3):247-56, 256.e2. PubMed ID: 24784001
[TBL] [Abstract][Full Text] [Related]
20. The ubiquitin ligase RNF181 stabilizes ERα and modulates breast cancer progression.
Zhu J; Li X; Su P; Xue M; Zang Y; Ding Y
Oncogene; 2020 Oct; 39(44):6776-6788. PubMed ID: 32973333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
